Text AA

HepConnect Grants

The Request for Proposals for the HepConnect Harm Reduction & Education Initiative is now closed. We will be carefully reviewing applications through a peer review process between now mid-September. We expect award announcements to be shared on Monday, September 16th. Thank you!

HepConnect Overview

The United States is experiencing rising rates of hepatitis C virus (HCV) infections, fueled by the nation’s growing opioid crisis. This issue is particularly acute in greater Appalachia, where the increase in injection drug use has led to a more than three-fold rise in HCV infection rates. In response to the intersecting opioid and HCV epidemics, Gilead Sciences launched HepConnect, a new five-year, multi-million-dollar initiative to help address the increase in HCV infections and support community partnerships in Indiana, Kentucky, North Carolina, Tennessee and West Virginia. HepConnect has three areas of focus:

  1. Expanding Screening & Linkage to Care,
  2. Support Harm Reduction & Community Education, and
  3. Activating Healthcare Infrastructure.

Under Expanding Screening & Linkage to Care, the focus is on expanding  screening and connecting patients to appropriate care. Under Activating Healthcare Infrastructure, the focus is on educating and expanding healthcare provider capacity and supporting the implementation of telemedicine and other innovative programs. This Request for Proposals is specific to Support Harm Reduction & Community Education, which focuses on building the capacity of new and existing syringe service programs and supporting initiatives that engage, educate, and mobilize community support for harm reduction. To learn more about HepConnect, click here.

Designed & Developed by Firefly Partners